MedPage Today July 30, 2024
— Newly approved prodrug has dual mechanism of action to improve tolerability
The FDA approved oral benzgalantamine (Zunveyl) to treat symptoms of mild-to-moderate Alzheimer’s disease, Alpha Cognition announced on Monday.
A prodrug of galantamine and an acetylcholinesterase inhibitor (AChEI), benzgalantamine has a dual mechanism of action designed to eliminate drug absorption in the gastrointestinal (GI) tract and potentially improve tolerability.
Galantamine was approved in 2001 as Razadyne to treat Alzheimer’s symptoms. It is available in several generic formulations and sometimes is purchased as dietary supplements.
Galantamine is thought to work by elevating acetylcholine levels in the brain to improve memory and cognitive function. Unlike the recently approved anti-amyloid drugs lecanemab (Leqembi) and donanemab (Kisunla), galantamine is not designed to modify...
Today's Sponsors
Today's Sponsor